Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial

Publikation

Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial

Ehrmann, Dominic; Eichinger, V.; Vesper, Iris; u. a. (2022): Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial, in: Trials, London: BioMed Central, Jg. 23, Nr. 1, S. 282, doi: 10.1186/s13063-022-06248-2.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
ORCID iDEhrmann, Dominic; Eichinger, V.; Vesper, Iris; Kober, J.; Kraus, M.; Schäfer, V.; ORCID iDHermanns, Norbert; Kulzer, Bernhard; Silbermann, Stephan
Titel der Zeitschrift
Trials
ISSN
1745-6215
Verlagsangabe
BioMed Central : London
Erscheinungsjahr
2022
Jahrgang
23
Heft
1
Sprache(n)
Englisch
DOI
Abstract

Background:

Diabetes self-management is a mainstay of diabetes care, but the implementation of self-management regimens into daily life is complex and often results in discouragement and distress. Modern approaches such as smartphone-based self-management applications are therefore needed to support people with diabetes. Since reimbursability would increase the availability of such digital applications to people with diabetes, we designed a study that meets all scientific and methodological requirements set by the German Digital Healthcare Act to allow reimbursement for a specific application (mySugr PRO). Here, we report the protocol of this study that aims at evaluating the efficacy of the digital self-management application with regard to patient-reported outcomes and medical benefits.

Methods/design:

This multicenter, open-label, randomized, parallel-group, controlled trial will evaluate the health care effects and medical benefits of mySugr PRO. A total of 466 people with diabetes will be randomly allocated (2:1 randomization) to the interventional group (n = 311) that will use the digital self-management application during the 12-week study period or the control group (n = 155; no usage of the application). Baseline and follow-up examinations will assess diabetes distress as the primary endpoint as well as empowerment, HbA1c, blood glucose data, self-management, general well-being, and treatment satisfaction as secondary endpoints. Statistical analyses will use an intention-to-treat procedure (using multiple imputation for missing values) as well as a per-protocol approach for sensitivity analysis.

Discussion:

To the best of our knowledge, this study will be one of the largest diabetes-specific evaluations of a digital health application supporting people with diabetes in their diabetes self-management that follow the requirements of the German Digital Healthcare Act.

Trial registration:

German Clinical Trial Register DRKS00022923. Registered on 22 October 2020.

GND-Schlagwort(e)
Diabetes mellitus
Selbstmanagementtherapie
E-Health
Freie Schlagwort(e)
Diabetes
Self-management
Diabetes distress
Digital health application
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
YC 7200
Peer Reviewed
ja
Internationale Verbreitung
ja
Open-Access-Zeitschrift
ja
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
12.09.2023

Permalink: https://fis.uni-bamberg.de/handle/uniba/90660 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 16.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.